and the ANRS CO12 CirVir and CHANGH groups Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence-based monitoring. The objective of this study was to estimate the cost-effectiveness of complying with HCC screening guidelines. The economic evaluation compared surveillance of patients with cirrhosis as recommended by the guidelines ("gold-standard monitoring") to "real-life monitoring" from the health care system perspective. A Markov model described the history of the disease and treatment course including current first-line curative treatment: liver resection, radiofrequency ablation (RFA), and liver transplantation. Transition probabilities were derived mainly from two French cohorts, CIRVIR and CHANGH. Costs were computed using French and U.S. tariffs. Effectiveness was measured in life years gained (LYG). An incremental cost-effectiveness ratio (ICER) was calculated for a 10-year horizon and tested with one-way and probabilistic sensitivity analyses. The cost difference between the two groups was $648 ($87,476 in the gold-standard monitoring group vs. $86,829 in the real-life monitoring group) in France and $11,965 ($93,795 vs. $81,829) in the United States. Survival increased by 0.37 years (7.18 vs. 6.81 years). The ICER was $1,754 per LYG in France and $32,415 per LYG in the United States. The health gain resulted from earlier diagnosis and access to first-line curative treatments, among which RFA provided the best value for money. Conclusion: Our results indicate that gold-standard monitoring for patients with cirrhosis is cost-effective, attributed to a higher probability of benefiting from a curative treatment and so a higher survival probability. (HEPATOLOGY 2017;65:1237-1248 H epatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor. It is responsible for over 700,000 deaths worldwide each year.
H epatocellular carcinoma (HCC) is the most frequent primary malignant liver tumor. It is responsible for over 700,000 deaths worldwide each year. (1) In France, the yearly incidence is around 8,000 and increasing. (2) HCC, in almost all cases, occurs in patients with chronic liver disease, most often at the stage of cirrhosis, and resulting from chronic infection by hepatitis C or B virus, excessive alcohol consumption, or nonalcoholic steatohepatitis. Patients remain asymptomatic for a long time; many do not receive appropriate disease management and have irregular surveillance. ( 3) Yet, the annual incidence of HCC at this stage ranges between 1% and 7%, depending on both the cause of underlying liver disease and its potential control, particularly in the case of antiviral treatment.
Curative treatments (liver resection [LR] , radiofrequency ablation [RFA] , and liver transplantation [LT] ) are limited to early-stage tumors. (7) The clinical practice guidelines endorsed by the French National Authority for Health, (8) in line with all other guidelines from Europe, the United States, and Asia, (9) (10) (11) (12) recommend biannual ultrasound monitoring in order to detect HCC at a curable stage. Nevertheless, fewer than 20% of patients with cirrhosis are effectively enrolled in surveillance programs, and late-stage tumor detection is frequent. (12, 13) 60% to 70% of patients enrolled in a surveillance program receive HCC curative treatment versus 20% for those not in the program. (14) The survival benefits of this surveillance have furthermore been challenged in recent years, (15) mostly because of inherent limitations in data interpretation such as lead-time bias and randomized studies that failed attributable to patients' refusal of inclusion. (16) The cost-effectiveness of surveillance for HCC in patients with cirrhosis was investigated in retrospective, (17) noncomparative studies or models comparing surveillance versus no surveillance, (18, 19) different surveillance techniques, (20) or different curative treatment. (21, 22) These studies have found a wide range of incremental cost-effectiveness ratios (ICERs), depending on the populations, strategies, and curative treatments. They have not, to our knowledge, addressed the issue of the organization of health care delivery and compared current with recommended practice. (22) In order to provide evidence for policy making at the national level, our objective was to assess the costeffectiveness of enforcing "gold-standard" monitoring with biannual ultrasound as compared to current practice.
Materials and Methods
We developed a Markov model to simulate patients with a diagnosis of compensated cirrhosis, by liver disease stage and treatment choice. We compared the surveillance according to the recommendations ("goldstandard monitoring") to what is observed in real life ("real-life monitoring") in terms of incidence, survival, and costs associated with cirrhosis and HCC. The time horizon was 10 years. A discount rate of 4% was applied to both outcomes and costs after the first year. The economic evaluation was conducted from the perspective of the French and U.S. health care systems in two separate analyses. The base year of analysis for cost was 2015. We followed the French and CHEERS guidelines for economic evaluation and modeling. (23, 24) 
POPULATION
The target population was the population of patients with compensated cirrhosis. A fictive cohort of 1,000 patients was run through the model. It was representative of the age and sex distribution of the target population, with an age of 55 years upon inclusion in the cohort and 65% of men. (25) ARTICLE INFORMATION: 
STRATEGIES
Gold standard consisted of biannual ultrasound surveillance. In case of nodule suspicion, a recall policy included additional imaging examination, magnetic resonance imaging (MRI) or computerized tomography (CT), and liver biopsy, if needed, based on the most recent international guidelines. (26) Specialists' consultations and tests each year for patients with cirrhosis with or without nodules were added. With regard to the appropriate threshold for tumor size, the European Association for the Study of the Liver/European Organization for Research and Treatment of Cancer guidelines published in 2012 stated that the noninvasive diagnosis of 1-to 2-cm lesions remains a challenging issue. (26) In these circumstances, the experts recommended to use two coincidental techniques while only one imaging technique was declared sufficient for focal lesions above 2 cm. In order to avoid introducing biases attributed to high rates of falsepositive diagnosis, we considered the 2-cm threshold in our model.
DATA SOURCES
We used two prospective, multicentric French cohorts: the ANRS CO12 CirVir (25) supplemented by information on recommended tests drawn from current guidelines (27) and CHANGH (13) cohorts. The ANRS CO12 CirVir cohort, sponsored and funded by the ANRS (France REcherche Nord & Sud Sida-HIV H epatites-FRENSH), is a prospective cohort describing the clinical course of compensated viral cirrhosis based on periodical data collection and analysis of predefined outcomes. CHANGH is a large, prospective cohort of patients with HCC recruited from primary care centers in France and followed over a 5-year period. A French multicenter, randomized trial comparing 3-month versus 6-month U.S. surveillance provided information on the incidence rate of HCC. LT survival was drawn from the Biomedicine Agency report (28) and outcomes after RFA from case series. (29) 
MODEL STRUCTURE
The health states were chosen to describe the natural history and medical management of patients with compensated cirrhosis. The simplified state transition model is presented in Fig. 1 and detailed models in Supporting Figs. S1 to S3. Patients entered the model in the "Compensated cirrhosis" state; upon being diagnosed with nodules or with liver cancer, they transited to "Nonmalignant nodules" or "HCC" states. Curative treatments of HCC included surgical LR, percutaneous RFA, and LT. We used the current distribution for each first-line curative treatment in France based on cohort data: 16% of patients had access to LR, 72% RFA, and 12% LT in the gold-standard monitoring group (25) versus 34%, 38%, and 28%, respectively, in the real-life monitoring group. (13) These percentages represented actual treatments and took into account access limitations, such as organ availability.
Patients requiring palliative care received chemoembolization, systemic therapy (sorafenib), or other palliative care. After liver resection or radiofrequency treatment, patients could transit to "Successfully treated" and then to " Relapse." The states "Nonmalignant nodules" and "Successfully treated" were transitory states where patients remained for a maximum 2 years. After LT, patients remained in the "Successfully treated" state until death or HCC relapse. Patients in "Relapse" could only transit to one of two curative treatments: percutaneous RFA or LT. Death was an absorbing state combining disease-specific mortality with age-and sexspecific mortality. Cycle duration was 3 months. Transition probabilities were derived from cumulative probabilities using the declining exponential approximation of life expectancy method. (30) All transition probabilities are presented in Supplement 1.
HEALTH OUTCOME
The outcome used in the model was survival. Each health state was associated with a survival rate and survival was accrued over a 10-year period.
COSTS French Costs
In the real-life monitoring group, the cost of managing cirrhosis with <20-mm nodules was estimated on the basis of the annual cost of a cirrhosis in the longterm illness scheme of the French social Health Insurance.
(31) In the gold-standard monitoring group, we added the cost of two additional ultrasounds and specialist consultations each year for cirrhosis, and of four additional ultrasounds and specialist consultations plus one MRI or CT scan each year for nodules exploration. In the real-life monitoring group, the costs of successfully treated patients were estimated on the basis of the annual cost of care of a HCC in the long-term illness scheme.
(31) In the gold-standard monitoring group, the extra costs of four specialist consultations, four ultrasounds, and one MRI or CT scan were added each year. The costs of curative HCC treatments were estimated from the 2012 French national hospital claims database (Program of medicalization of information systems, Programme de M edicalisation des Systèmes d'Information), which collects linked, anonymized medical records of all French inpatient and day-case admissions in both public and private hospitals using diagnosis-related groups (DRGs). We extracted all hospital stays corresponding to LR, radiofrequency, or LT for which HCC was coded as the primary or secondary diagnosis along with all related readmissions within 3 months of the initial hospitalization. For patients in the "successfully treated posttransplantation" state, the costs of the follow-up were obtained by extracting all hospital stays corresponding to either transplant monitoring or transplant failure 3 months posttransplantation. Other posttransplantation treatments were added.
Palliative treatment combined hospitalization for chemoembolization, systemic therapy (sorafenib), and other palliative care. We identified all hospital stays corresponding to chemoembolization or palliative care for which HCC was coded as the primary or secondary diagnosis as well as readmissions within the next 3 months. Given that sorafenib is taken at home, we added a specialist consultation to the cost of the drug.
Resource utilization was estimated for each health state and accrued over the 10-year period of the model. Out-of-hospital resources were valued from the SHI tariffs and hospital stays the DRG tariff to which were added daily supplements for intensive care.
(32-34) Costs were updated to 2013 US Dollars.
U.S. Costs
To estimate the U.S. cost of each health state or each health-state component, a systematic review of the literature was undertaken. We matched cost data from 2010 to 2016 studies to the health states in our model. (16, (35) (36) (37) Unit costs for surveillance tests and procedures were retrieved from Medicare Outpatient Prospective Payment System. French and U.S. unit costs are presented in Supplement 2.
ECONOMIC EVALUATION
The economic evaluation estimated costs and life years of gold-standard versus real-life monitoring. Because both the probability to access a first-line curative treatment and the type of first-line curative treatment chosen are important, we ran a global analysis with a fixed case mix of the three first-line treatments (RFA, surgical resection, and LT) and three subanalyses where we assumed that only one of the three first-line treatments would be used. These subanalyses allow a direct comparison of the efficiency of first-line treatments.
Results are presented as ICER per life year gained (LYG; which are calculated as the difference in the expected cost produced by the two strategies divided by the difference in the expected life years).
We performed one-way sensitivity analyses on the following parameters: probability of detecting nodules in patients with cirrhosis with real-life monitoring; probability of diagnosing curable HCC in patients with cirrhosis with gold-standard monitoring; and palliative chemotherapy cost, discount rate (Supplement 3). We also changed the share of each first-line curative treatment in the gold-standard monitoring group: from 85% to 38% for RFA; from 7% to 34% for LR; and from 8% to 28% for LT. We also tested the effect of an identical distribution of first-line curative treatments in both groups using the real-life monitoring group distribution (34% LR, 38% RFA, and 28% LT), and, finally, we tested the reverse distribution of each first-line curative treatment between the two groups (34% LR, 38% RFA and 28% LT in the goldstandard monitoring group vs. 16% LR, 72% RFA, and 12% LT in the real-life monitoring group).
A probabilistic sensitivity analysis was also performed to address the uncertainty of the model parameters. Statistical distributions were assigned to the model parameters to evaluate the uncertainty around the point estimates. We used a beta distribution for transition probabilities and costs and a uniform distribution for discount rate. The parameter variations are presented in Supplement 3. Uncertainty in all model parameters was assessed using a Monte Carlo simulation, drawing parameter values at random 1,000 times from the appropriate corresponding distributions. The results from the simulations were used to generate cost-effectiveness acceptability curve to explore the probability that gold-standard monitoring would be economically attractive compared to real-life monitoring at any cost-effectiveness threshold.
We tested internal validity of the Markov model by calculating the life expectancy of patients for each strategy and comparing our results to French data. (38, 39) 
Because all data were obtained from secondary sources without patient-level information, this study was exempt from human subjects review and approval. The authorization numbers were 905463 for the ANRS CO12 CirVir cohorts and CCTIRS 07.454bis for the CHANGH cohort.
Results

BASE CASE
The 10-year overall survival was 76% in the goldstandard monitoring group and 67% in the real-life monitoring group. In the gold-standard monitoring, 37% patients were diagnosed with liver cancer over the 10-year period versus 34% in the real-life group. Of the population diagnosed with cancer, 79% patients had access to one of the three curative options as firstline treatment in the gold-standard monitoring versus 43% in the real-life monitoring.
The cost difference between the two groups was $648 ($87,476 in the gold-standard monitoring group versus $86,829 in the real-life monitoring group) with French costs and $11,965 ($93,795 vs. $81,829) with U.S. costs. Mean survival increased by 0.37 years with the gold-standard monitoring (7.18 vs. 6.81 years). The global ICER was $1,754 per LYG with French costs and $32,415 per LYG with U.S. costs assuming the predefined case mix of first-line treatments in the two groups, with a clear predominance of RFA in the gold-standard monitoring group (57% vs. 15%). When the effect of the difference in first-line curative treatment case mix was canceled by attributing to all patients the same treatment, the French ICERs were $3,022 per LYG for a patient undergoing RFA in first-line curative treatment, $6,387 per LYG for LR, and $23,594 per LYG for LT (Table 1A ). The U.S. ICERs were $39,165 per LYG for a patient undergoing RFA in first-line curative treatment, $38,776 per LYG for LR, and $164,557 per LYG for LT (Table  1B) .
SENSITIVITY ANALYSES
In the one-way sensitivity analyses, the maximum ICER was $14,124 per LYG with French costs and $95,495 with U.S. costs, with an average incremental cost, respectively, of $5,578 and $37,715 and an average difference of 0.39 LYGs when attributing the reverse mix of each first-line curative treatment. The second maximum ICER was $10,091 per LYG with French costs and $74,999 per LYG with U.S. costs, with an average incremental cost, respectively, of $3,895 and $28,946 and an average difference of 0.39 LYGs when attributing to both groups the mix of first-line curative treatment found in the real-life monitoring group distribution. In the best-case scenario, the minimum ICER was negative with French costs, indicating dominance of the gold-standard monitoring, $-799 per LYG with an average incremental cost of $-290 and an average efficiency difference of 0.36 LYGs attributed to the variation of the distribution of each first-line curative treatment in the gold-standard monitoring group in favor of RFA. With U.S. costs, this ICER was $21,099 per LYG, with an average incremental cost of $7,659 ( Table 2) . We tested the influence of U.S. surveillance costs on the ICER and found that a 50% reduction in costs of clinic visits and imaging divided the ICER by 3, at $10,050 per LYG.
The probabilistic sensitivity analyses found that the gold-standard monitoring was more effective and more expensive than the real-life monitoring (Fig. 2) . Fifty percent of replications fell below $3,374 per LYG and 90% below $4,729 per LYG (Fig. 3) with French costs and, respectively, below $44,329 per LYG and $60,097 per LYG with U.S. costs. In France, the average ICER was $9,492 per LYG (SD 5 $2,218/LYG) for a patient undergoing LR in first-line curative treatment, $6,076 per LYG (SD 5 $2,020/LYG) for a patient undergoing RFA in first-line curative treatment and $27,665 per LYG (SD 5 $4,401/LYG) for a patient undergoing LT in first-line curative treatment. In the United States, the ICERs for LR, radiofrequency, and LT were, respectively, $57,378 per LYG (SD 5 $14,907/LYG), $59,215 (SD 5 $15,816/ LYG) per LYG, and $189,139 per LYG (SD 5 $28,532/LYG; Fig. 4) .
In order to test the model's validity, we ran simulations beyond the 10-year time horizon and found a predicted average life expectancy for patients with diagnosed liver cirrhosis of 25.3 years in the goldstandard monitoring group and 21.4 years in the reallife monitoring group for patients of 55 years of age, which was consistent with the average life expectancy of the French population of 29.2 years at 55 and 24.6 years at 60.
Discussion
Following guidelines for screening patients of 55 years of age with compensated cirrhosis increased life expectancy by an average 5 months and was costeffective at $1,754 per additional LYG with French costs and at $32,415 per additional LYG with U.S. These results are weighted by the probability of each first-line treatment in the gold-standard and real-life groups and used for the calculation of the final ICER. The respective mixes of first-line curative treatment in each group that are used to estimate the average ICER are shown.
costs. To be considered cost-effective, the ICER should be under the willingness to pay threshold of the payer, which can be estimated below 3 times the gross domestic product per capita. (40, 41) The large difference between French and U.S. efficiency ratios is explained by the 4-to 10-fold difference in unit costs for surveillance (clinic visits, tests) and for first-line curative treatments, respectively.
The 0.37-year gain in life expectancy resulted from the combination of earlier detection, higher access to curative first-line treatment, and better treatment results. Gold-standard monitoring allowed more patients to gain access to the more cost-effective curative options (RFA or resection). This finding was shown to be robust in the sensitivity analyses: Earlier detection increased the likelihood of being eligible for RFA, which is the cheapest curative treatment, whereas later detection not only reduced the likelihood of curative treatment, but also increased the proportion of LT among the curative treatments. Access to LT, as well as to the other curative treatments, was based on cohort data and represented actual, not ideal, access to treatment in France. (13, 42) We assumed that gold-standard monitoring could be obtained at the sole cost of increasing consultations and noninvasive testing without extensive system redesign. Patients in the real-life monitoring group, which we used as a reference, were already monitored at irregular intervals in hospital clinics and would not require specific disease management programs, but rather a stricter monitoring schedule. The one-way sensitivity analyses showed that ICER was most sensitive to changes in the mix of first-line curative treatment, for example, goldstandard surveillance was most efficient when RFA was the curative treatment of choice. Our model was not designed to allow direct comparisons between the three options, because it is unlikely that all three would be available to the same patients. The scatter plots on Fig. 4 show that the efficacy (on the horizontal axis) is roughly the same regardless of the curative treatment chosen, but that the costs vary greatly between the lowest (RFA) and highest (LT). Emerging treatments, such as selective internal radiation therapy using yittrium-90, microwave, irreversible electroporation, or multipolar RFA, could be added to the model as results become available.
The overall gain in life expectancy might be considered modest, given the time and effort required to ensure a semiannual surveillance of patients with cirrhosis. This result, however, is good by cancer screening standards. A simulation model of yearly biomarker-ultrasound screening for HCC in Taiwan found a gain of less than 0.02 person years and a life expectancy of 23.4 years (compared to 25.3 years in our model) for patients with liver cirrhosis starting screening at age 55. (43) Lin et al. found a gain of 0.081 quality-adjusted life years (QALYs) over 30 years using semiannual screening. (44) In lung cancer, screening adds 0.0316 to 0.059 QALYs, (45) in colorectal cancer 0.2-0.8 QALYs, (46) and in prostate cancer the gain varies from 0.017 to 0.064 QALYs. Of note, the 0.064-QALY gain with prostate cancer screening led to a controversy on whether this was too small to warrant adoption. (47, 48) With regard to HCC screening, a review of the economic literature suggested that biannual surveillance would be cost-effective in populations where the yearly incidence is higher than 1.5%-3.0%. (49) In this review, all 14 studies except one were based on Markov models. Overall cost-effectiveness results reported in the literature vary widely depending on the surveillance strategy and treatments chosen. Both U.S. and French results fall in the lower range of the cost-effectiveness ratios reported, from $8,090/QALY to $284,000 per LYG. This difference is explained by both lower treatment costs, particularly in France (because of RFA), and higher QALY gains attributed to the younger age of the models' populations (several models begin surveillance at 40 years). The yearly incidence of HCC in published models was, on average, 4% (range, 2%-6%), lower than the incidence reported in the CHC 2000 trial with a cumulative 24-month incidence of 13.2%: This difference would also account for our better efficiency results. (14) In the United States, the ICER is close to the usually accepted threshold of $30,000-50,000 per LYG, although the systematic surveillance would not be as attractive as it is in France at the current costs for clinic visits and imaging.
The CirVir cohort used to estimate the transition probabilities in the gold-standard monitoring group consisted of patients with viral cirrhosis only excluding other types of cirrhosis, whereas data on real-life monitoring came from the CHANGH cohort, which included all types of cirrhosis. This limitation in the comparability of patients was, however, mitigated by the inclusion of data obtained from other cohorts or trials, which included patients with cirrhosis and/or HCC patients affected by other causes of chronic liver disease, in particular, the CHC 2000 trial in which excessive alcohol consumption was the predominant etiology. We did not include quality-of-life information and did not compute a cost utility (cost per QALY) ratio. Other researchers noted the paucity of data on direct patient-elicited utilities for different stages of liver diseases, and we chose not to use different estimation methods and different patient samples 
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Radiofrequency ablation 72 38 Liver resection 16 34 Liver transplantation 12 28 In the probabilistic analysis, the average incremental cost was $891 with French costs and $11,580 with U.S. costs, the average difference was 0.26 LYG, and the average ICER was $3,535 per LYG (SD 5 $908/LYG) with French costs and $46,063 per LYG (SD 5 $10,010/LYG) with U.S. costs.
FIG. 3.
ICER distribution and acceptability curve corresponding to the scatter plot for the model combining all treatment options as defined in Fig. 2 . costs. The figure shows that RFA, when feasible, is more effective than either surgical option. LT has the highest ICER. Gains in efficiency can be therefore obtained by substituting radiofrequency to surgical treatments, either by making this treatment option more broadly available or by increasing the share of patients who can benefit from RFA as a first-line curative treatment.
for our model. Our ICER is therefore lower (in other words, better) than those of studies that computed a cost per QALY given that the quality of life of patients with liver cirrhosis or liver cancer is poor, ranging from 0.76 to 0.63. (27) Our results, however, remained robust within a wide range of utility values, given that weighing the life years gained by 0.5 would not push the ICER above the $60,000/QALY threshold.
In conclusion, in patients with cirrhosis, HCC surveillance performed in line with recommendations is life-saving and cost-effective. These results highlight the pivotal role of intervention strategies aimed at improving HCC surveillance rates and quality in case of cirrhosis, both at the health care providers and patients' levels.
